Kwality Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE552U01010
  • NSEID:
  • BSEID: 539997
INR
1,450.00
-13.5 (-0.92%)
BSENSE

Mar 25

BSE+NSE Vol: 26.9 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Kwality Pharma
NGL Fine Chem
Shukra Pharma.
Lincoln Pharma.
Amrutanjan Healt
Windlas Biotech
Hester Bios
Jagsonpal Pharma
Morepen Labs.
Solara Active
Indoco Remedies

Why is Kwality Pharmaceuticals Ltd ?

1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.13 times
2
With a growth in Net Profit of 87.79%, the company declared Outstanding results in Dec 25
  • The company has declared positive results for the last 8 consecutive quarters
  • ROCE(HY) Highest at 19.03%
  • INVENTORY TURNOVER RATIO(HY) Highest at 5.04 times
  • OPERATING PROFIT TO INTEREST(Q) Highest at 12.08 times
3
Market Beating performance in long term as well as near term
  • Along with generating 93.50% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Kwality Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Kwality Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Kwality Pharma
93.5%
1.73
53.96%
Sensex
-3.52%
-0.27
12.93%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
23.30%
EBIT Growth (5y)
18.44%
EBIT to Interest (avg)
16.92
Debt to EBITDA (avg)
1.06
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.96
Tax Ratio
26.50%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.83%
ROCE (avg)
17.19%
ROE (avg)
16.81%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
26
Industry P/E
32
Price to Book Value
5.19
EV to EBIT
18.44
EV to EBITDA
15.00
EV to Capital Employed
4.31
EV to Sales
3.42
PEG Ratio
0.41
Dividend Yield
NA
ROCE (Latest)
20.07%
ROE (Latest)
16.91%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

33What is working for the Company
ROCE(HY)

Highest at 19.03%

INVENTORY TURNOVER RATIO(HY)

Highest at 5.04 times

OPERATING PROFIT TO INTEREST(Q)

Highest at 12.08 times

DEBT-EQUITY RATIO(HY)

Lowest at 0.38 times

NET SALES(Q)

Highest at Rs 123.44 cr

PBDIT(Q)

Highest at Rs 29.95 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 24.26%

PBT LESS OI(Q)

Highest at Rs 22.65 cr.

PAT(Q)

Highest at Rs 16.60 cr.

EPS(Q)

Highest at Rs 15.42

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Kwality Pharma

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 22.65 cr has Grown at 110.89%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 16.60 cr has Grown at 94.7%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
At Rs 123.44 cr has Grown at 46.24%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 12.08 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Inventory Turnover Ratio- Half Yearly
Highest at 5.04 times and Grown
each half year in the last five half yearly periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales - Quarterly
Highest at Rs 123.44 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 29.95 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 24.26%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 22.65 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 16.60 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 15.42
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Debt-Equity Ratio - Half Yearly
Lowest at 0.38 times
in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio